Chemical formula: C₂₆H₂₃FIN₅O₄ Molecular mass: 615.395 g/mol PubChem compound: 11707110
Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EE01 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SPEXOTRAS Powder for oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| MEKINIST Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Trametinib is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Brazil (BR)
Canada (CA)
Cyprus (CY)
Ecuador (EC)
Finland (FI)
Hong Kong (HK)
Israel (IL)
Italy (IT)
Japan (JP)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Singapore (SG)
South Africa (ZA)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
